首页 | 本学科首页   官方微博 | 高级检索  
     

放疗对血清miR-150-5p和miR-23a-3p表达水平的影响
引用本文:闫青洁,王平,李敏杰,宋俊华,韩林,李杰,杜沙沙,张云飞,张巧,吕玉民. 放疗对血清miR-150-5p和miR-23a-3p表达水平的影响[J]. 中华放射医学与防护杂志, 2022, 42(11): 851-856
作者姓名:闫青洁  王平  李敏杰  宋俊华  韩林  李杰  杜沙沙  张云飞  张巧  吕玉民
作者单位:郑州大学公共卫生学院, 郑州 450001;河南省第三人民医院 河南省职业病医院河南省辐射生物与流行病学医学重点实验室, 郑州 450052;郑州大学第五附属医院, 郑州 450052
基金项目:河南省医学科技攻关计划项目(LHGJ20190815);中国医学科学院放射医学研究所辐射生物剂量与生物标志物联合实验室项目(JSQTHTKT20200901664)
摘    要:目的 通过采集肿瘤患者放疗前后外周血,探讨照射对人外周血血清miR-150-5p、miR-23a-3p表达的影响,以期为寻找辐射生物标志物提供科学依据。方法 以2021年10月至2022年3月63例行放疗的肿瘤患者为研究对象,采用实时荧光定量PCR(qPCR)方法,检测患者放疗前后外周血血清miR-150-5p与miR-23a-3p的相对表达水平。比较两种miRNAs放疗前后在患者外周血血清中的差异表达变化,分析其与肿瘤类型等因素的关系。结果 放疗后,患者外周血血清miR-150-5p与miR-23a-3p的相对表达量明显低于放疗前(t=4.97,Z=-2.77,P<0.05)。不同的肿瘤类型中,乳腺癌、食管癌和其他消化道肿瘤患者放疗后miR-150-5p的相对表达量降低(t=3.47、2.47、2.87,P<0.05),消化道肿瘤患者放疗后miR-23a-3p相对表达量下降(Z=-1.99,P<0.05)。在放疗前、后miR-150-5p的表达改变均不受性别、年龄、化疗和肿瘤类型等因素影响(P>0.05),而miR-23a-3p的表达改变在放疗后受性别、年龄和化疗等因素影响(t=2.04、 -3.34、-2.29,P<0.05)。结论 放疗可影响肿瘤患者血清中miR-150-5p的表达,其有作为辐射生物学标志物的潜力。

关 键 词:放疗  血清  miR-150-5p  miR-23a-3p  生物标志物
收稿时间:2022-07-20

Effect of radiotherapy on the expression levels of miR-150-5p and miR-23a-3p in serum of tumor patients treated with tumor radiotherapy
Yan Qingjie,Wang Ping,Li Minjie,Song Junhu,Han Lin,Li Jie,Du Shash,Zhang Yunfei,Zhang Qiao,Lyu Yumin. Effect of radiotherapy on the expression levels of miR-150-5p and miR-23a-3p in serum of tumor patients treated with tumor radiotherapy[J]. Chinese Journal of Radiological Medicine and Protection, 2022, 42(11): 851-856
Authors:Yan Qingjie  Wang Ping  Li Minjie  Song Junhu  Han Lin  Li Jie  Du Shash  Zhang Yunfei  Zhang Qiao  Lyu Yumin
Affiliation:College of Public Health, Zhengzhou University, Zhengzhou 450001, China;Henan Key Laboratory of Medicine on Radiobiology and Epidemiology, Third People''s Hospital of Henan Province, Henan Province Occupational Disease Hospital, Zhengzhou 450052, China;Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Abstract:Objective To investigate the effect of irradiation on the expression of miR-150-5p and miR-23a-3p in human peripheral blood serum by collecting peripheral blood of tumor patients before and after radiotherapy, so as to provide scientific basis for finding radiation biomarkers.Methods A total of 63 tumor patients treated with radiotherapy from October 2021 to March 2022 were enrolled in this study. The relative expression levels of miR-150-5p and miR-23a-3p in peripheral blood serum in these patients were detected using the real-time fluorescence quantitative PCR (qPCR) before and after radiotherapy. The differential changes in the expression levels of the two miRNAs in the peripheral blood serum of the patients before and after radiotherapy were compared, and their relationships with factors such as cancer types were analyzed.Results The relative expression levels of miR-150-5p and miR-23a-3p in peripheral blood serum of the patients after radiotherapy were significantly lower than those before radiotherapy (t = 4.97, Z = -2.77, P< 0.05). Among different cancer types, the relative expression level of miR-150-5p in the patients with breast cancer, esophageal cancer, or other digestive tract cancer decreased after radiotherapy (t = 3.47, 2.47, 2.87, P< 0.05), and the relative expression level of miR-23a-3p in the patients with digestive tract cancer decreased after radiotherapy (Z = -1.99, P< 0.05). The changes in the expression level of miR-150-5p before and after radiotherapy were not affected by gender, age, chemotherapy, and cancer type (P > 0.05). By contrast, the changes in the expression level of miR-23a-3p before and after radiotherapy were significantly affected by gender, age, and chemotherapy (t=2.04, -3.34, -2.29, P<0.05). Conclusions The expression of miR-150-5p in the serum of tumor patients may be affected by radiotherapy, which has the potential to be used as a biological indicator of radiation.
Keywords:Radiotherapy  Serum  miR-150-5p  miR-23a-3p  Biomarker
点击此处可从《中华放射医学与防护杂志》浏览原始摘要信息
点击此处可从《中华放射医学与防护杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号